Evidence map›Paper›PMID 34723462›Full record

ArticleACS chemical biology2021

Modulation of Specialized Metabolite Production in Genetically Engineered

Zhiran Ju, Wei Zhou, Hattan A Alharbi, Daniel C Howell, Taifo Mahmud

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS chemical biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Zhiran JuDepartment of Pharmaceutical Sciences, Oregon State University, Corvallis, Oregon 97331-3507 United States.
Wei ZhouDepartment of Pharmaceutical Sciences, Oregon State University, Corvallis, Oregon 97331-3507 United States.ORCID 0000-0001-7540-2459
Hattan A AlharbiDepartment of Pharmaceutical Sciences, Oregon State University, Corvallis, Oregon 97331-3507 United States.
Daniel C HowellDepartment of Pharmaceutical Sciences, Oregon State University, Corvallis, Oregon 97331-3507 United States.
Taifo MahmudDepartment of Pharmaceutical Sciences, Oregon State University, Corvallis, Oregon 97331-3507 United States.ORCID 0000-0001-9639-526X
Oregon State University · US

Funding

Biosynthetic studies and development of ribomimetic-based anti-infectivesR01AI129957 · NIAID · OREGON STATE UNIVERSITY · PI MAHMUD, TAIFO · 2018 to 2022
$1.8M
Acquisition of a 700 MHz NMR SpectrometerS10OD018518 · OD · OREGON STATE UNIVERSITY · PI BARBAR, ELISAR J · 2015 to 2015
$1.3M
NIAID NIH HHS R01 AI129957NIH HHS S10 OD018518
6 · The paper itself

Abstract

Filamentous soil bacteria are known to produce diverse specialized metabolites. Despite having enormous potential as a source of pharmaceuticals, they often produce bioactive metabolites at low titers. Here, we show that inactivation of the pactamycin, NFAT-133, and conglobatin biosynthetic pathways in

Indexed as

Organisms, Genetically ModifiedAnti-Bacterial AgentsAntineoplastic AgentsCell Line, TumorDrug Screening Assays, AntitumorGenes, BacterialHSP90 Heat-Shock ProteinsHumansMicrobial Sensitivity TestsMolecular StructureOxazolesPolyketidesPolyketide SynthasesProtein BindingStreptomycesSubstrate SpecificityAnti-Bacterial AgentsAntineoplastic AgentsconglobatinHSP90 Heat-Shock ProteinsOxazolesPolyketidesPolyketide Synthases

Identifiers

PMID34723462
PMCPMC8604789
OpenAlexW3209022285

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.